908-909 / 1578
SABR for operable patients
ASTRO guidelines
PRO 2017
For patients with “standard operative risk” (i.e.
with anticipated
operative mortality of <1.5%
) and stage I NSCLC, SABR is not
recommended as an alternative to surgery outside of a clinical trial.
American Society for Radiation Oncology (
ASTRO
) Guidelines 2017
Endorsed by the European Society for Radiotherapy & Oncology, the Royal Australian and New Zealand
College of Radiologists, and the International Association for the Study of Lung Cancer